IRTC

IRHYTHM HLDGS (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

iRhythm Holdings has reported 24% annual revenue growth over the last two years and recently moved into positive free cash flow, signaling improved operating efficiency and stronger commercial traction for its wearable cardiac monitoring services.

Price target updates for iRhythm Holdings now reflect a slightly lower fair value of US$171.33 compared with the prior US$178.93.

iRhythm Holdings (IRTC) has drawn fresh attention after recent trading left the share price at US$108.66, with the stock down 3% over the past month and 2% over the past 3 months.

iRhythm Holdings has delivered a 59.8% share price gain over the past five years, yet its recent slide over the last year has pushed many investors to ask whether the cash flows behind the business still justify the current US$108.66 price tag.

iRhythm Holdings (NasdaqGS: IRTC) reported a cybersecurity incident involving unauthorized access to certain patient data that is now under investigation.

iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how patient monitoring stocks fared in Q2, starting with iRhythm (NASDAQ:IRTC).

iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.

iRhythm Holdings (IRTC) informed investors that Board member and Audit Committee chair Brian Yoor resigned for personal reasons on August 12, 2026. Existing director Karen McGinnis will step in to chair the Audit Committee.

iRhythm’s stock price has taken a beating over the past six months, shedding 27.5% of its value and falling to $115.17 per share. This may have investors wondering how to approach the situation.

Revenue jumped 20% while margins expanded, and the company raised full-year guidance.